Astrazeneca

FromAstraZeneca ([email protected])
Sent withMailchimp
Subject (78)Positive results from PREVAIL Phase III trial at AANEM/MGFA Scientific Session
Preheader (150)Gefurulimab demonstrates statistically significant and clinically meaningful improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) at w
Typography
Arial
Colors
Text Analysis
Body Words185
Subject Words11
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px848 px
X-Spam Score-0.1
Preheader OptimizedNo
Timing
Day of WeekThursday
TimeOvernight

Positive results from PREVAIL Phase III trial at AANEM/MGFA Scientific Session

Gefurulimab demonstrates statistically significant and clinically meaningful improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) at w
Positive results from PREVAIL Phase III trial at AANEM/MGFA Scientific Session